Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany's ClinIT receives government grant

This article was originally published in Scrip

Executive Summary

The German federal ministry for economics and technology has provided a six-figure grant to Freiburg-based ClinIT and the faculty for databases and information systems of the local Albert-Ludwigs University. The move was made within the Central Innovation Scheme for Medium-sized Businesses development programme. ClinIT intends to develop a new tool for the automatic analysis of data quality in clinical studies and thus optimise the existing scheme when such analysis is carried out for each project. The tool should provide project and data managers who have no specific programming skills with an opportunity to measure and control the quality of data and processes over large-volume libraries and databases, along with cost-effectiveness. ClinIT, which was founded in 2001, specialises in the development and supply of information systems for clinical trials.

Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC007407

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel